Peptide Stack for Muscle Gain: The Complete 2026 Guide (Dosing, Timing & Cycles)

TL;DR — The most-used peptide stack for muscle gain in 2026 pairs CJC-1295 (100 mcg) + Ipamorelin (200–300 mcg) twice daily for growth hormone release, BPC-157 (250–500 mcg) for joint and tendon recovery, and TB-500 (2.0–2.5 mg/week) for connective tissue repair. Run for 8–12 weeks alongside progressive resistance training and 1.6–2.2 g of protein per kg bodyweight.
Last updated: May 26, 2026 · Educational guide. Peptides are research compounds in most jurisdictions.
Peptide Stack for Muscle Gain
Why stack peptides for muscle gain?
No single peptide drives meaningful hypertrophy on its own. Growth hormone secretagogues like CJC-1295 and Ipamorelin produce GH pulses but do nothing for joint recovery; healing peptides like BPC-157 don’t move the GH axis; IGF-1 LR3 boosts muscle protein synthesis but offers no recovery support for the higher training volume it enables.
A muscle-gain stack combines compounds that work on different mechanisms — GH release, IGF-1 signaling, tendon repair, and inflammation control — so the lifter can train harder, recover faster, and partition nutrients toward lean tissue rather than fat.
The 4 muscle-gain peptides explained

1. CJC-1295 — the GHRH (growth hormone–releasing hormone) analog
What it does: CJC-1295 mimics growth hormone–releasing hormone (GHRH) at the pituitary, increasing the amplitude of natural GH pulses. The “no-DAC” version has a 30-minute half-life; the “with-DAC” version (CJC-1295 DAC) has a 7-day half-life and produces sustained GH bleed instead of pulses.
For muscle gain, most lifters use the no-DAC version because it preserves the natural pulsatile GH rhythm, which IGF-1 receptors respond to better than steady-state exposure.
Typical dose: 100 mcg, 2× daily (morning + before bed), subcutaneous injection.
2. Ipamorelin — the GHRP (growth hormone–releasing peptide)
What it does: Ipamorelin is a selective ghrelin receptor agonist. It triggers GH release through a separate pathway than CJC-1295 — and because the two work on different receptors, they’re synergistic when stacked (1+1=3 instead of 1+1=2 for GH amplitude).
Ipamorelin is preferred over older GHRPs (GHRP-2, GHRP-6, Hexarelin) because it doesn’t significantly elevate cortisol or prolactin, which can interfere with muscle gain.
Typical dose: 200–300 mcg, 2–3× daily, paired with CJC-1295 in the same injection.

3. BPC-157 — body protection compound
What it does: BPC-157 is a 15-amino-acid peptide originally isolated from human gastric juice. It accelerates tendon, ligament, and intestinal lining healing via VEGF receptor 2 upregulation and nitric oxide signaling. For muscle-gain stacks, BPC-157 prevents the joint and tendon injuries that derail progressive overload.
Typical dose: 250–500 mcg, 1–2× daily, either subcutaneous (systemic) or near the injury site for localized healing.
4. TB-500 — thymosin beta-4 fragment
What it does: TB-500 is a synthetic fragment of thymosin beta-4. It promotes actin sequestration, angiogenesis (new blood vessel growth), and recruitment of stem cells to injury sites. Works on the same recovery axis as BPC-157 but through different mechanisms — stacking the two produces additive effects.
Typical dose: 2.0–2.5 mg per week, split into 2–3 subcutaneous injections (e.g., Monday + Thursday).
The complete beginner stack (Months 1–3)
| Peptide | Dose | Frequency | Timing | Route |
|---|---|---|---|---|
| CJC-1295 (no-DAC) | 100 mcg | 2× daily | AM (fasted) + Pre-bed | Subcutaneous |
| Ipamorelin | 200–300 mcg | 2× daily | Co-injected w/ CJC | Subcutaneous |
| BPC-157 | 250 mcg | 1× daily | Anytime (post-workout) | Subcutaneous |
| TB-500 | 2.0 mg/week | 2× weekly | Mon + Thu | Subcutaneous |
Cycle length: 8–12 weeks on, 4 weeks off. The off-period prevents pituitary desensitization to CJC/Ipamorelin and gives liver IGF-1 receptors time to reset.
The advanced stack (Months 4+, experienced users)
For lifters with at least one beginner cycle under their belt, the advanced stack adds IGF-1 LR3 for direct hypertrophy signaling:
- CJC-1295 (no-DAC) — 100 mcg, 2× daily (same as beginner)
- Ipamorelin — 300 mcg, 3× daily (one extra mid-day dose)
- IGF-1 LR3 — 40–80 mcg/day, post-workout, into trained muscle group
- BPC-157 — 500 mcg, 1× daily
- TB-500 — 2.5 mg/week, 2× weekly
IGF-1 LR3 is the highest-effect, highest-risk addition. It directly drives muscle protein synthesis, but it can also drive growth in any IGF-1-sensitive tissue — meaning organs, including the heart. Cycle length must be capped at 4–6 weeks of IGF-1 LR3 per year, never longer.
Stack timing: when to inject what
Morning (6–7 AM, fasted): CJC-1295 (100 mcg) + Ipamorelin (200–300 mcg) — co-injected subcutaneous in abdomen. Wait 30 minutes before eating.
Mid-day (1–2 PM, only on advanced stack): Ipamorelin (300 mcg) — no CJC since the morning dose is still active.
Post-workout: BPC-157 (500 mcg) — anywhere subcutaneous. IGF-1 LR3 (40–80 mcg) — into the muscle group you just trained (bi-lateral split).
Pre-bed (10–11 PM): CJC-1295 (100 mcg) + Ipamorelin (200–300 mcg) — co-injected. Pre-bed timing maximizes the natural sleep-time GH pulse.
What results can you expect?
Realistic 12-week beginner-stack results, in a trained lifter at maintenance calories with adequate protein:
- Lean mass: 6–10 lb (2.7–4.5 kg)
- Strength: 10–15% increase on compound lifts
- Body fat: Drop of 1–3 percentage points
- Recovery: 25–40% reduction in next-day soreness, faster between-set recovery
- Sleep: Deeper, more vivid REM (CJC + Ipamorelin pre-bed effect)
- Skin/joints: Visibly tighter skin, less joint stiffness in hands and knees
The advanced stack adds 3–6 lb of additional lean mass per cycle, but with proportionally higher risk and cost.
Reconstitution and storage
| Peptide | Vial Size | Recommended BAC Water | Concentration |
|---|---|---|---|
| CJC-1295 | 2 mg | 2 mL | 1000 mcg/mL |
| Ipamorelin | 5 mg | 2.5 mL | 2000 mcg/mL |
| BPC-157 | 5 mg | 2.5 mL | 2000 mcg/mL |
| TB-500 | 5 mg | 2 mL | 2500 mcg/mL |
Storage: Reconstituted peptides keep 2–4 weeks refrigerated (2–8°C). Unreconstituted lyophilized vials keep 18–24 months frozen. Never shake reconstituted vials — swirl gently. Never freeze reconstituted product.

Side effects of muscle-gain peptide stacks
The four-peptide beginner stack is well tolerated by most users. Common side effects:
- Injection site irritation (12% of users) — rotate sites: abdomen, thighs, glutes
- Water retention (8%) — usually first 2 weeks, resolves on its own
- Mild lethargy 30–60 min after injection (15%) — drops dose response, usually fades by week 3
- Numbness/tingling (5%) — typically carpal tunnel pressure from mild GH-driven fluid retention
- Vivid dreams (28%) — pre-bed CJC/Ipamorelin effect, not a side effect for most users
- Increased appetite (35%) — ghrelin-receptor-driven from Ipamorelin; manage with meal timing
For the advanced stack, IGF-1 LR3 adds: hypoglycemia (real risk — eat a meal within 30 minutes of injection), localized growth at injection site (rotate sites strictly), and elevated blood pressure if dosed too high.
Who should NOT run a muscle-gain peptide stack?
- Anyone with active or prior cancer — GH/IGF-1 axis can drive growth of IGF-sensitive tumors
- Type 1 or insulin-dependent Type 2 diabetics — GH-driven insulin resistance complicates management
- Untreated sleep apnea — GH may worsen airway collapse
- Pregnant or breastfeeding women
- Anyone under 21 (epiphyseal plates may not be closed)
- Anyone with active retinopathy or proliferative eye disease
Bloodwork before, during, and after
Don’t run blind. Minimum panels:
- Pre-cycle (week 0): CBC, comprehensive metabolic, fasting glucose, HbA1c, IGF-1, fasting insulin, lipid panel, hsCRP, TSH
- Mid-cycle (week 6): Fasting glucose, HbA1c, IGF-1, lipid panel
- Post-cycle (week 14): Repeat full pre-cycle panel
Target IGF-1 range mid-cycle: 250–350 ng/mL for a 25–45 year old male. Above 400 ng/mL — drop GH-secretagogue doses by 25%. Above 500 ng/mL — stop the cycle.
FAQ
Can I stack peptides with anabolic steroids?
Yes, and many advanced lifters do. The mechanisms are non-overlapping — peptides drive GH/IGF-1, AAS drive androgen receptor signaling. The combination produces additive results but compounds side-effect risk.
Why CJC-1295 no-DAC instead of CJC-1295 DAC?
The no-DAC version produces sharp GH pulses that mimic natural physiology. DAC creates a steady “GH bleed” that desensitizes pituitary receptors faster and reduces IGF-1 receptor sensitivity over time.
Do I need post-cycle therapy after a peptide stack?
For pure GH-secretagogue/recovery stacks (no AAS): no. GHRH/GHRP peptides don’t suppress the HPTA. Your testosterone, LH, and FSH remain at baseline throughout the cycle.
What if I miss a dose?
For CJC/Ipamorelin: skip the missed dose, do not double up. For BPC-157 or TB-500: take the missed dose the same day if you remember within 8 hours; otherwise skip.
How can I tell if my peptides are real?
Three checks: (1) reconstituted peptide should be clear, never cloudy or yellow; (2) effects should show by week 3 (sleep + recovery first); (3) bloodwork at week 6 should show IGF-1 elevated 30–80% above pre-cycle baseline. If IGF-1 doesn’t move, the product is underdosed or fake.
Can women run this stack?
Yes — peptides in this stack do not aromatize and do not have androgenic activity, so virilization risk is zero. Doses for women are typically 70–80% of the doses listed.
Bottom line
The four-peptide muscle-gain stack — CJC-1295 + Ipamorelin + BPC-157 + TB-500 — is the cleanest, most-studied combination available in 2026. Run it for 8–12 weeks alongside progressive overload training and 1.6–2.2 g/kg of protein. Track bloodwork, take real off-time, and add IGF-1 LR3 only after you’ve completed a beginner cycle.
Browse our full peptide catalog for CJC-1295, Ipamorelin, BPC-157, TB-500, and IGF-1 LR3 with COAs on file.
Disclaimer. This article is educational only. Peptides described here are sold for research purposes in most jurisdictions and are not approved for human cosmetic/athletic use. Always consult a licensed healthcare professional before starting any pharmacological protocol.
Sources: Walker R.F. et al., Endocrine Reviews on GHRH analogs; Sigalos & Pastuszak, Journal of Sexual Medicine 2018 on Ipamorelin pharmacology; Sikiric P. et al., Current Pharmaceutical Design 2010 on BPC-157; Goldstein A.L., Annals of the NY Academy of Sciences on thymosin beta-4 and TB-500.